1. What Is the Structural Heart Market?
The Structural Heart Market covers transcatheter and minimally invasive devices used to repair or replace defective heart valves, close cardiac septal defects, and treat structural heart disease without open-heart surgery. Interventional cardiologists and cardiac surgeons at certified structural heart centers use Structural Heart products in patients with valvular heart disease, congenital structural anomalies, and cardiac shunt lesions requiring transcatheter intervention. The market spans TAVR systems, edge-to-edge mitral and tricuspid repair devices, transcatheter mitral and tricuspid replacement platforms, and atrial and ventricular septal defect closure systems. ESC and ACC structural heart disease guidelines inform patient selection, risk stratification, and heart team assessment requirements for transcatheter structural heart interventions.
2. Structural Heart Market Size & Forecast
3. Emerging Technologies
- Transcatheter mitral valve repair clip systems use a catheter-delivered bivalve clip that grasps and approximates the mitral leaflets at the regurgitant gap, reducing mitral regurgitation severity by creating a double-orifice valve without open surgery. Abbott's MitraClip G4 and Edwards Lifesciences' PASCAL are the commercial transcatheter mitral repair clip systems with published randomized trial outcome data for primary and functional mitral regurgitation.
- Transcatheter tricuspid valve repair systems deliver edge-to-edge clips to the tricuspid leaflets through transseptal catheter access, reducing severe tricuspid regurgitation in patients ineligible for isolated tricuspid surgery due to high operative risk. Abbott's TriClip, the first FDA-approved transcatheter tricuspid device, and Edwards Lifesciences' PASCAL for tricuspid use represent the initial commercial transcatheter tricuspid repair platforms.
- Atrial septal defect occluder systems use a self-expanding nitinol mesh device delivered via transseptal catheter to close secundum atrial septal defects by deploying two disc components across the atrial septal opening. Gore's Cardioform Septal Occluder and Abbott's Amplatzer Septal Occluder are established commercial septal closure devices used at structural heart programs and community interventional cardiology laboratories.
- Transcatheter aortic valve replacement platforms with valve-in-valve delivery features enable implantation within failed surgical bioprostheses, restoring hemodynamic function without repeat sternotomy in patients with structural valve deterioration. Edwards Lifesciences' Sapien 3 Ultra RESILIA and Medtronic's Evolut FX have dedicated valve-in-valve sizing guides and deployment recommendations for common failed bioprosthesis brands.
Similar technologies are also transforming adjacent markets. Learn more in our Left Atrial Appendage Closure Market.
4. Key Market Opportunity
One of the most substantial opportunities in the Structural Heart Market is the transcatheter mitral valve replacement segment, which has the potential to serve the large mitral regurgitation population that is not suitable for repair approaches due to complex leaflet anatomy, prior repair failure, or severe degenerative changes requiring valve replacement rather than leaflet approximation. The transcatheter tricuspid valve market represents a high-growth commercial opportunity in an entirely new therapeutic category, with Abbott's TriClip FDA approval establishing reimbursement pathways and commercial infrastructure that will support rapid volume expansion as community structural heart centers adopt the technique. Geographic expansion of structural heart certification programs across Asia Pacific, Latin America, and the Middle East is generating new TAVR, mitral repair, and septal closure procedure volumes as governments invest in cardiac intervention infrastructure and establish reimbursement frameworks. The development of an integrated structural heart failure management strategy integrating TAVR, mitral repair, and CRT device selection through coordinated heart team assessment represents a multidisciplinary care model that could substantially increase per-patient device revenue at comprehensive structural heart programs.
5. Top Companies in the Structural Heart Market
The following organisations hold leading positions in the Structural Heart Market. The full report provides revenue share, SWOT analysis, and competitive benchmarking for each player.
- Edwards Lifesciences (Sapien 3 Ultra, PASCAL)
- Abbott (MitraClip G4, TriClip, Amplatzer)
- Medtronic (Evolut, Tendyne)
- Boston Scientific (ACURATE neo2)
- Gore Medical (Cardioform)
- Occlutech
- JenaValve
- HighLife Medical
- NaviGate Cardiac Structures
- Anteris Technologies
6. Market Segmentation
The Structural Heart Market is analysed across 4 segmentation dimensions. Revenue data, growth rates, and competitive intensity by sub-segment are available in the full report.
| Segmentation | Sub-Segments |
|---|---|
| By Device Category | Transcatheter Aortic Valve Replacement Mitral Valve Repair Mitral Valve Replacement Tricuspid Valve Interventions Septal Defect Closure |
| By Approach | Transcatheter Minimally Invasive Surgical |
| By End User | Certified Structural Heart Centers Hybrid Operating Room Facilities |
| By Geography | North America Europe Asia Pacific Latin America Middle East and Africa |
7. Key Market Trends (2026–2034)
Three major forces are shaping the Structural Heart Market trajectory over the forecast period:
Transcatheter Mitral Valve Repair Is Expanding Its Patient Reach as Indications Broaden from Degenerative to Functional Mitral Regurgitation.Abbott's MitraClip transcatheter mitral valve repair system uses edge-to-edge leaflet clip technology to reduce mitral regurgitation severity without open surgery, and the COAPT randomized trial published in 2018 established that MitraClip reduces heart failure hospitalizations and mortality in selected patients with functional mitral regurgitation attributable to left ventricular dilation. The COAPT trial results established a new category of heart failure with functional mitral regurgitation as a transcatheter mitral repair indication, substantially expanding the eligible population beyond degenerative primary mitral regurgitation patients who were the initial clinical focus. Abbott's MitraClip G4 and the newer PASCAL mitral repair system from Edwards Lifesciences are the principal commercial transcatheter mitral repair platforms with published clinical outcome data. The mitral repair market is growing at a faster rate than TAVR as functional mitral regurgitation indication expansion reaches the much larger heart failure population with mitral regurgitation.
Transcatheter Tricuspid Valve Interventions Are Emerging as a New Structural Heart Therapeutic Category Addressing a Disease with Limited Prior Treatment Options.Severe tricuspid regurgitation is associated with high mortality and significant morbidity including ascites, lower extremity edema, and progressive right ventricular failure, but has historically been undertreated due to the high surgical risk of isolated tricuspid valve surgery in elderly and frail patients. Transcatheter tricuspid devices including the TRILUMINATE PIVOTAL trial CLASP system and the TRISCEND II trial Tricento system have generated Phase 2 and pivotal trial data supporting FDA review submissions for transcatheter tricuspid valve repair and replacement. Abbott's TRILUMINATE Pivotal trial of the TriClip system received FDA approval in 2023 as the first transcatheter tricuspid device approved in the United States, establishing the commercial foundation for the transcatheter tricuspid market. The transcatheter tricuspid segment represents one of the highest-growth opportunities within the structural heart market as an entirely new therapeutic category addressing a previously untreatable patient population.
Patent Foramen Ovale Closure Is a High-Volume Structural Heart Procedure with Established Randomized Evidence Supporting Stroke Recurrence Prevention.Patent foramen ovale is present in approximately 25 percent of the adult population, and the REDUCE, CLOSE, and RESPECT randomized trials collectively established that transcatheter PFO closure reduces recurrent cryptogenic stroke incidence compared to anticoagulation alone in patients under 60 years with PFO-associated stroke. Gore Medical, Abbott, and Occlutech manufacture commercial PFO closure device systems approved for cryptogenic stroke prevention after demonstrated PFO association, with the Gore Cardioform Septal Occluder and Abbott's Amplatzer PFO Occluder holding US and international approvals. PFO closure procedures are performed at both high-volume structural heart centers and community interventional cardiology practices where the technique has been taught through proctored case programs. The PFO closure segment sustains consistent volume demand as neurologists increase PFO evaluation rates in young stroke patients following guideline updates incorporating the randomized trial evidence.
For related market intelligence, see the Tavr Market.
8. Segmental Analysis
By device category, the Transcatheter Aortic Valve Replacement segment dominated the Structural Heart Market in 2025, representing the majority of structural heart procedure revenue as the most mature transcatheter structural heart intervention with established low, intermediate, and high surgical risk indication coverage. The Transcatheter Tricuspid Valve Interventions segment is the fastest-growing device category, advancing from clinical trial status to early commercial launch following Abbott's TriClip FDA approval in 2023, with procedure volumes expected to grow significantly as community structural heart programs adopt transcatheter tricuspid repair technique through training programs.
By end user, Certified Structural Heart Centers lead overall market revenue, while Hospitals with Hybrid Operating Rooms are registering the highest growth rate as new structural heart program certifications proliferate at community hospital systems seeking to offer transcatheter structural heart procedures.
9. Regional Analysis
Regional demand patterns across the Structural Heart Market reflect differences in regulation, technological maturity, and capital investment.
Largest Market Share
North America dominated the Structural Heart Market in 2025, accounting for approximately ~44% of global market revenue, driven by the highest TAVR and transcatheter mitral repair procedure volumes globally, established structural heart certification program infrastructure at major cardiac surgery centers, and the commercial leadership of Edwards Lifesciences and Abbott in the TAVR, mitral repair, and tricuspid device segments. Moreover, CMS coverage determinations supporting TAVR, transcatheter mitral valve repair, and PFO closure in indicated populations sustain broad patient access and institutional investment in hybrid operating room infrastructure. In addition, the active FDA regulatory engagement on transcatheter mitral replacement and tricuspid intervention submissions maintains a product pipeline that sustains North American leadership in next-generation structural heart technology. The established procedure volume, reimbursement framework, and device innovation leadership sustain North American dominance in the Structural Heart Market through the forecast period.
Highest CAGR Region
Asia Pacific is projected to register the highest CAGR in the Structural Heart Market through 2034, advancing at approximately ~19.5%, driven by large and growing populations of untreated valvular heart disease patients across China, India, Japan, and Southeast Asia, expanding structural heart certification programs at major cardiac centers, and government health insurance reimbursement establishment for TAVR and transcatheter mitral repair in Japan, South Korea, and China. The region benefits from active domestic structural heart device development in China, where Venus Medtech, Microport, and other manufacturers have developed domestically approved TAVR and septal closure systems competing with international brands at government hospital procurement programs. Moreover, rheumatic mitral valve disease affecting younger populations in India and Southeast Asia represents a substantial transcatheter mitral replacement opportunity as dedicated rheumatic mitral valve transcatheter systems are developed. The combination of valvular disease burden, program expansion, and domestic device development positions Asia Pacific for sustained growth outperformance through 2034.
10. Full Report with Exclusive Insights
The complete published market report includes an in-depth analysis of market dynamics, industry trends, competitive landscape, regional outlook, and future growth opportunities. The study provides detailed market sizing and forecasts across key segments and geographies, along with comprehensive insights into drivers, restraints, opportunities, challenges, technological advancements, regulatory landscape, and evolving consumer and industry trends. The report also features company profiles, strategic developments, market share analysis, and actionable recommendations to support informed business decision-making. Additionally, the syndicated report package typically includes forecast datasets, charts and figures, research methodology, and analyst support for strategic interpretation and planning.
Advanced Strategic & Custom Intelligence
In addition to the standard syndicated report package, TrendX Insights can provide the following advanced strategic analyses and customized intelligence solutions for any market:
Standard Report Coverage
- • Competitor Analysis
- • Country Trade Analysis
- • Import & Export Analysis
- • Porter’s Five Forces Analysis
- • SWOT Analysis by Companies
- • TrendX Insights Quadrant Positioning
- • Pricing Analysis
- • Detailed Macro-Economic Indicators Assessment
- • List of Raw Material Suppliers
- • Regulatory Framework Assessment
- • Supply Chain Resilience Mapping
- • Value Chain Analysis
- • Technology Adoption Trends and Innovation Tracking
- • Custom Company Profiling and Benchmarking
Exclusive Sections With Additional Cost
- • Agentic AI Readiness Score
- • TAM, SAM, and SOM Analysis
- • AI Act & Privacy Compliance Audit
- • Channel Partner Ecosystem Mapping
- • China + 1 Strategy Analysis
- • Circular Economy Opportunities Assessment
- • Competitor Benchmarking KPI Analysis
- • Country-Level Opportunity Mapping
- • Digital Maturity Matrix
- • Ecosystem Interdependency Mapping
- • ESG & Decarbonization Roadmap
- • Geopolitical Friction Scorecard
- • Geopolitical Risk Assessment
- • Humanoid Workforce Impact Analysis
- • Investment Heatmap
- • List of Distributors and Channel Partners
- • Market Entry Strategy Assessment
- • Mergers & Acquisitions (M&A) Analysis
- • Patent & Intellectual Property (IP) Analysis
- • Pilot Project Analysis
- • Potential High-Growth Region/Country Investment Assessment
- • Product Comparison Analysis
- • Product Revenue Analysis
- • R&D Investment Analysis in Emerging Technologies
- • Raw Material Scarcity Forecast
Note: For highly customized requirements, deeper strategic assessments, company-specific intelligence, or tailored consulting support, please contact TrendX Insights.
Full Report with Exclusive Insights
Available to clients on request
Explore Our Published Reports Library
This page covers market-level data estimates. For comprehensive published research reports including full methodology, primary data, and detailed company profiles, browse the TrendX Insights Published Reports Library.
Visit Published Reports Library ›11. Related Market Reports
Frequently Asked Questions
The Structural Heart Market was valued at USD 12.47 Bn in 2025 and is projected to reach USD 43.20 Bn by 2034, growing at a CAGR of 14.8% over the 2026–2034 forecast period.
The Structural Heart Market is projected to grow at a CAGR of 14.8% from 2026 to 2034.
North America dominated the Structural Heart Market in 2025, accounting for approximately ~44% of global market revenue, driven by the highest TAVR and transcatheter mitral repair procedure volumes globally, established structural heart certification program infrastructure at major cardiac surgery centers, and the commercial leadership of Edwards Lifesciences and Abbott in the TAVR, mitral repair, and tricuspid device segments.
The leading companies in the Structural Heart Market include Edwards Lifesciences (Sapien 3 Ultra, PASCAL), Abbott (MitraClip G4, TriClip, Amplatzer), Medtronic (Evolut, Tendyne), Boston Scientific (ACURATE neo2), Gore Medical (Cardioform), Occlutech, JenaValve, HighLife Medical, NaviGate Cardiac Structures, Anteris Technologies.
Transcatheter mitral valve repair is expanding its patient reach as indications broaden from degenerative to functional mitral regurgitation.
By device category, the Transcatheter Aortic Valve Replacement segment dominated the Structural Heart Market in 2025, representing the majority of structural heart procedure revenue as the most mature transcatheter structural heart intervention with established low, intermediate, and high surgical risk indication coverage.
How to Order
Purchasing a TrendX Insights report is straightforward. Our process is designed to be transparent and risk-free for buyers, with a 20% upfront model and full delivery before the balance payment.
This is the price of the syndicated report. Any custom inclusions beyond the Table of Contents will be scoped and priced separately. For the full list of what is covered in the syndicated report, refer to the Table of Contents tab.
A curated, condensed version of this report for students, researchers, and academic institutions. Ideal for thesis work, dissertations, and academic projects. Delivered as PDF to your institutional email.
Valid student ID or institutional email required. For educational and non-commercial use only.